Search clinical trials for: ETBX-011

Total 3048 results

National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
National Cancer Institute (NCI)

Completed

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Neoplasms | Breast Cancer | Lung Cancer | Prostate Cancer | Colon Cancer

United States
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
ImmunityBio, Inc.

Withdrawn

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
ImmunityBio, Inc.

Unknown

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Pancreatic Cancer

United States
NantCell, Inc.

Completed

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Thyroid Cancer

United States
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Metastatic Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Chordoma | Unresectable Malignant Neoplasm

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma Recurrent

United States
NantBioScience, Inc.

Unknown

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Cancer

United States
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)

Triple Negative Breast Cancer (TNBC)

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
Pendulum Therapeutics

Completed

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
Achieve Life Sciences

Completed

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada
University of North Carolina, Chapel Hill

Completed

Analysis of Orthodontic Tooth Movement Using 3D Imaging

Malocclusion | Tooth Crowding | Dental Crowding

United States
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Hutchison Medipharma Limited

Completed

Phase I Clinical Trial in Healthy Male Volunteers

Inflammatory Bowel Diseases
Nexel Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of NP-011 in Healthy Volunteers

Myocardial Infarction

Australia
AbbVie

Completed

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Japan, Korea, Republic of, Taiwan
Taiga Biotechnologies, Inc.

Not yet recruiting

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Myelofibrosis | Acute Myelogenous Leukemia

Italy, Croatia
Taiga Biotechnologies, Inc.

Not yet recruiting

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Severe Combined Immunodeficiency

Israel
McMaster University

Completed

Accessibility of the World Health Organization's eTB Catalogue of Recommendations

Tuberculosis

Canada
Prolacta Bioscience

Recruiting

Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancy

United States
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Cancer | Refractory Cancer | Tumor, Solid

Israel, United States
Damascus University

Completed

The Use of an Esthetic Twin Block for Patients With Mandibular Retrusion

Class II Malocclusion

Syrian Arab Republic
Xoft, Inc.

Enrolling by invitation

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

Non-melanoma Skin Cancer

United States
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Solid Tumor

China
Eliem Therapeutics (UK) Ltd.

Completed

Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

Lumbosacral Radiculopathy

United States
Eliem Therapeutics (UK) Ltd.

Completed

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy

United States
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
Orionis Biosciences Inc

Recruiting

ORB-011 In Patients With Advanced Solid Tumors (ORB)

Advanced Solid Cancer

United States
Celgene
Celgene Corporation

Terminated

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors

United States
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Anemia | Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm

United States
Heron Therapeutics

Completed

A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Postoperative Pain

United States
Fochon Pharmaceuticals, Ltd.

Recruiting

Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）

Advanced Solid Tumor

China
University of British Columbia
United States Department of Defense

Completed

Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

Prostate Cancer

Canada
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Incurable Disease

United States

3

Subscribe